We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Turns Down FibroGen’s Roxadustat for Anemia
FDA Advisory Panel Turns Down FibroGen’s Roxadustat for Anemia
San Francisco biotech FibroGen’s investigational drug for anemia linked to chronic kidney disease (CKD) should not receive FDA approval, the agency’s Cardiovascular and Renal Drugs Advisory Committee said yesterday.